The Medicines Patent Pool Welcomes New Executive Director Greg Perry

GENEVA, 14 NOVEMBER 2012: The Medicines Patent Pool is pleased to announce the appointment of Greg Perry, currently Director General of the European Generic Medicines Association, as its new Executive Director, effective 7 January 2013.

“We are excited to have Greg Perry take the helm at the Patent Pool. His long experience representing the generic pharmaceutical industry in Europe and globally will be invaluable in taking forward the work of the Medicines Patent Pool as it continues seeking licences which will enable more people living with HIV to be treated with affordable generic drugs,” said Charles Clift, chair of the Medicines Patent Pool Governance Board.

“The Medicines Patent Pool is an innovative mechanism that can dramatically change the lives of people living with HIV while offering a win-win proposition for both businesses and public health. By creating a partnership between patent holders and generic producers through the Medicines Patent Pool, access to HIV medicines can be expanded to the 34 million people currently living with HIV that will all likely need treatment. Through patent pooling, quality, cutting edge treatments can be made more easily available for all people with HIV, and the development and production of critically needed fixed dosed combinations (FDCs) and paediatric formulations can be enhanced. I look forward to joining this exciting project and working with all concerned stakeholders so as to make a significant contribution to increasing access to medicines,” said Greg Perry.

Greg Perry joins the Medicines Patent Pool with over 20 years experience in pharmaceutical and intellectual property policy issues. Greg has an extensive track record of high-level advocacy with governments, international organisations, pharmaceutical stakeholders and NGOs and has a personal commitment to improving public health. Greg founded the European Generic Medicines Association in 1993 and has been its Director General since 1999. He is also a founding member of the International Generic Pharmaceutical Alliance and has been on its management committee since 1997. Prior to joining the generic industry, Greg advised corporate and non-governmental organisations on European Union legislation and policy.

Greg was awarded the Golden Cross of Merit of the Republic of Poland in 2004 for contribution to industry and European integration. He was granted an honorary life fellowship of the Organisation for Professionals in Regulatory Affairs (TOPRA) in 2005 for contributions to European pharmaceutical regulatory issues. Greg is also member of the Standing Advisory Committee before the European Patent Office.

“When I first came across the idea of a Medicines Patent Pool several years ago, I had a vision of an organisation that could demonstrate a new business model for the future – one that could work for all stakeholders: originator pharmaceutical companies, generic companies, and most importantly people living with HIV. In Greg Perry, the Pool has chosen someone who can help take that vision forward,” said Philippe Douste-Blazy, chair of innovative financing mechanism UNITAID’s Executive Board. UNITAID, an organisation devoted to increasing treatment for HIV, tuberculosis and malaria, helped create the Pool in 2010.

About the Medicines Patent Pool

The Medicines Patent Pool, founded by UNITAID in 2010, aims to lower the prices of HIV medicines and facilitate the development of better-adapted HIV medicines, such as simplified “fixed-dose combinations” and special formulations for children. It does this by creating a pool of relevant patents for licensing to generic manufacturers. Facilitating generic competition brings down prices and can help stimulate innovation. The Medicines Patent Pool has been endorsed by the World Health Organization, the UN High Level Meeting on AIDS, and the Group of 8 as a promising innovative approach to improve access to HIV medicines.

For more information, see, or contact MPP Communications at gro.looptnetapsenicidemnull@sserp.

Comments are closed.